CST, 4574S, FGF Receptor 3 (C51F2) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying FGFR3. Validated for WB,IP,IHC,IF. Available in 2 sizes. Highly specific and rigorously validated in-house, FGF Receptor 3 (C51F2) Rabbit Monoclonal Antibody (CST #4574) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Immunohistochemistry (Paraffin): 1:50 Immunofluorescence (Immunocytochemistry): 1:200 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 94065 . Protocol Available protocols: Western Blotting, Immunoprecipitation, Immunohistochemistry (Paraffin), Immunofluorescence (Immunocytochemistry) Specificity / Sensitivity FGF Receptor 3 (C51F2) Rabbit Monoclonal Antibody detects endogenous levels of FGF Receptor 3 protein. This antibody does not cross-react with other related family members. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a GST-FGFR-3 cytoplasmic domain fusion protein. Background Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases. There are four members of the FGF receptor family: FGFR1 (flg), FGFR2 (bek, KGFR), FGFR3, and FGFR4. Each receptor contains an extracellular ligand-binding domain, a transmembrane domain, and a cytoplasmic kinase domain (1). Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues (2). Seven tyrosine residues in the cytoplasmic tail of FGFR1 can be phosphorylated: Tyr463, 583, 585, 653, 654, 730, and 766. Tyr653 and Tyr654 are important for catalytic activity of activated FGFR and are essential for signaling (3). The other phosphorylated tyrosine residues may provide docking sites for downstream signaling components, such as Crk and PLCγ (4,5). Activating mutations within fibroblast growth factor receptor 3 (FGFR-3) are responsible for human skeletal dysplasias including achondroplasia and the neonatal lethal syndromes thanatophoric dysplasia types I and II (6). Several of these same FGFR-3 mutations as well as overexpression of FGFR-3 proteins have also been identified somatically in human cancers, including multiple myeloma, bladder carcinoma and cervical cancer (7). Thus, FGFR-3 may represent a potential target for therapy. Alternate Names ACH; achondroplasia, thanatophoric dwarfism; CD333; CEK2; FGFR-3; FGFR3; Fibroblast growth factor receptor 3; fibroblast growth factor receptor 3 variant 4; fibroblast growth factor receptor 3-S; HSFGFR3EX; hydroxyaryl-protein kinase; JTK4; tyrosine kinase JTK4 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 165, 145 and 125 Source/Isotype: Rabbit IgG